Phase II Study of RAD001 for Treatment of Refractory, Recurrent, Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Trial Profile

Phase II Study of RAD001 for Treatment of Refractory, Recurrent, Locally Advanced Squamous Cell Carcinoma of the Head and Neck.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Head and neck cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jan 2016 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017, as reported by ClinicalTrials.gov record.
    • 15 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Oct 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top